Medical device maker Boston Scientific Corporation (NYSE: BSX) reported financial results for the second quarter of 2023. The company also provided guidance for fiscal 2023.
- The company reported net sales of $3.599 billion for Q2, representing an 11% year-over-year increase, and an 11.6% growth on an organic basis
- Net income attributable to stockholders, on an unadjusted basis, was $261 million, compared to $246 million in the year-ago period
- Net income per share came in at $0.18 per share, slightly higher than the $0.17 per share reported last year
- Second-quarter adjusted earnings increased to $0.53 per share from $0.44 per share in the same period of last year
- The management expects net sales to grow in the range of 10.5% to 11.5% in fiscal 2023 on a reported basis, and 10-11% on an organic basis
- Full-year net income, including special items, is expected to be between $0.87 per share and $0.93 per share; the forecast for adjusted EPS is $1.96-$2.00
Most Popular
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
BLK Q4 Preview: BlackRock appears poised for another earnings beat
BlackRock, Inc. (NYSE: BLK), the largest asset management company, is set to publish its fourth-quarter 2025 results next week. The update is expected to shed light on how the firm’s
A look at Best Buy’s (BBY) progress on its growth strategy
Shares of Best Buy Co., Inc. (NYSE: BBY) fell over 3% on Wednesday. The stock has dropped 17% over the past 12 months. The consumer electronics retailer delivered sales and
